Purpose: The antitubulin agent monomethyl auristatin F (MMAF) induces potent antitumor
effects when conjugated via protease cleavable linkers to antibodies targeting internalizing …

Induction of apoptosis in endothelial cells is considered an attractive strategy to
therapeutically interfere with a solid tumor's blood supply. In the present paper, we …

Antibody-drug conjugates (ADCs) are promising therapies for haematological cancers.
Historically, their therapeutic benefit is due to ADC targeting of lineage-restricted antigens …

Rationale: Platelets are increasingly recognized as mediators of tumor growth and
metastasis. Hypothesizing that activated platelets in the tumor microenvironment provide a …

Disease relapse after treatment is common in triple-negative breast cancer (TNBC), ovarian
cancer (OVCA), and non–small cell lung cancer (NSCLC). Therapies that target tumor …

Background Antibody drug conjugate (ADC) showed potent therapeutic efficacy in several
types of cancers. The role of autophagy in antitumor effects of ADC remains unclear …

OBJECTIVE: To investigate the target delivery properties of RC48-ADC, a novel antibody
drug conjugate (ADC) comprising cytotoxic monomethyl auristatin E (MMAE) and an anti …

Background ZW49 is a novel ADC comprised of a HER2-targeting bispecific antibody
(directed against 2 non-overlapping HER2 epitopes) attached to a proprietary auristatin …

A chemically defined anti‐CXCR4–auristatin antibody–drug conjugate (ADC) was
synthesized that selectively eliminates tumor cells overexpressing the CXCR4 receptor. The …

Advanced-stage epithelial ovarian cancers are amongst the most difficult to treat tumors and
have proven to be refractory to most cytotoxic, molecularly targeted, or immunotherapeutic …